Adipokines in hereditary breast cancer patients and healthy relatives

Oncotarget. 2017 Sep 18;8(60):101255-101261. doi: 10.18632/oncotarget.21018. eCollection 2017 Nov 24.

Abstract

Background: The role of adipocytokines and ghrelin in hereditary breast cancer syndrome (HBCS) has never been tested.

Results: No significant differences in leptin, adiponectin and ghrelin plasma levels between cancer patients and healthy subjects was observed. Conversely, an higher level of adiponectin was shown in healthy subjects with BRCA 1/2 gene mutation vs those without (p < 0.03). Logistic regression analysis demonstrated that Adiponectin plasma level (OR 0.26; 95% CI:0.007-0.81; p < 0.02) and age (OR 5.51; 95% CI:1.78-19.71; p < 0.004) were the only factors independently associated with BMI; furthermore, Leptin plasma level (OR 0.23; 95% CI:0.06-0.76; p < 0.01) and age (OR 0.05; 95% CI:0.05-0.61; p < 0.007) resulted the only factors significantly associated with breast cancer.

Materials and methods: We analyzed blood plasma expression of leptin, adiponectin and ghrelin using Bio-Plex platform in 25 breast cancer patients with HBCS and in 38 healthy relatives. BRCA 1/2 gene status (presence of pathogenic mutations by direct molecular sequencing), clinical-pathological characteristics and Body Mass Index (BMI) of each subject were recorded.

Conclusions: Adiponectin confirms to be associated with BMI also in subjects with HBCS. Leptin plasma level seems a direct and independent biomarker of a breast cancer risk. A validation of Leptin as a circulating biomarker of breast cancer development in larger series of HBCS subjects is needed.

Keywords: BMI; BRCA; adipokines; breast cancer; hereditary.